Want to see XAIR full AI Analyst Report?
Earnings Data
Report Date
Aug 11, 2026Before Open (Confirmed)
Period Ending
2027 (Q1)Consensus EPS Forecast
―Last Year’s EPS
-1.53Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call communicated clear commercial progress: strong revenue growth (>107% to $7.7M), improved gross profit and operating results, high customer retention (~90%), expanded GPO relationships and global clearances, and a compelling product roadmap with Gen 2 that could materially expand the addressable market. Offsetting these positives are remaining sizable net losses ($33.2M), limited cash on hand ($17.3M) versus $21.6M of long-term debt, increased other expenses, a Nasdaq compliance-driven reverse split, and dependence on uncertain FDA timing for Gen 2 approval (which underpins 2027 guidance). Overall, momentum and execution improvements are evident, but material execution and financing/regulatory risks remain.Company Guidance
Strong Revenue Growth
Revenue increased more than 107% year-over-year to $7.7 million in fiscal 2026 (from $3.7 million in fiscal 2025), driven by higher demand in U.S. and international markets.
High Customer Retention and Expanded Commercial Reach
Customer renewal rate approximately 90%; signed a national purchasing agreement with a top-three U.S. GPO (third major GPO engagement), adding access to ~2,000 hospitals and complementing agreements with Premier and Vizient; regulatory clearance in over 45 countries and ongoing hospital evaluations/pilots.
Swing to Gross Profitability and Improved Operating Results
Gross profit improved by $300,000 versus a $1.7 million loss in the prior year (a ~$2.0 million swing to profitability). Combined with cost reductions and revenue growth, operating results improved by $15.5 million (a 35% improvement).
Significant Cost Reductions and Cash Burn Improvement
R&D expenses decreased 39% to $10.2 million (from $16.9 million) and SG&A decreased 27% to $19.1 million (from $26.0 million) primarily from prior restructuring; net cash burn (excluding financing) fell 56% to $19.1 million.
Gen 2 Platform Potential and Large TAM Expansion
Gen 2 LungFit PH (PMA supplement submitted June 2025) is positioned to offer transport capability, smaller footprint, simplified operation and ~4x longer duration between maintenance cycles. If approved and labeled for transport, management estimates U.S. addressable market could expand ~4x to ~$400 million and worldwide opportunity to >$1 billion.
Revenue Guidance Showing Growth Trajectory
First-time calendar 2026 revenue guidance of $8 million (~15% growth over calendar 2025) and calendar 2027 guidance of $16 million to $18 million (implying >110% year-over-year growth at the midpoint), with 2027 guidance assuming FDA approval and commercial launch of Gen 2 as planned.
XAIR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
XAIR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Jun 26, 2026 | $0.48 | $0.49 | +3.77% |
Feb 13, 2026 | $1.02 | $1.05 | +2.94% |
Nov 10, 2025 | $1.74 | $1.46 | -16.09% |
Aug 12, 2025 | $3.16 | $2.45 | -22.47% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Beyond Air (XAIR) report earnings?
Beyond Air (XAIR) is schdueled to report earning on Aug 11, 2026, Before Open (Confirmed).
What is Beyond Air (XAIR) earnings time?
Beyond Air (XAIR) earnings time is at Aug 11, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is XAIR EPS forecast?
Currently, no data Available